Related Experiment Video
Updated: Apr 23, 2026
10:27
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
23.9K
Emerging drugs for coeliac disease
Peter D Mooney1, Marios Hadjivassiliou, David S Sanders
1Royal Hallamshire Hospital, Regional GI and Liver Unit , Glossop Rd, Sheffield, S10 2JF , UK p_d_mooney@hotmail.com.
Expert Opinion on Emerging Drugs
|September 16, 2014
Summary
New treatments for coeliac disease are needed as many patients struggle with a gluten-free diet (GFD). Oral glutenase supplements show promise for improving gluten degradation, offering a potential breakthrough therapy.
Area of Science:
- Gastroenterology
- Immunology
- Celiac Disease Pathogenesis
Background:
- Coeliac disease affects 1% of adults as an autoimmune gluten-sensitive enteropathy.
- A gluten-free diet (GFD) is the primary treatment, but 30% of patients experience persistent symptoms.
- Adherence to a GFD is challenging, and no alternative therapies are currently licensed.
Purpose of the Study:
- To review alternative treatment strategies for coeliac disease beyond a GFD.
- To discuss potential therapeutic targets and advanced-stage development products.
Main Methods:
- Literature review of alternative treatments for coeliac disease.
- Analysis of potential therapeutic targets and their developmental status.
Main Results:
- Oral glutenase supplements aim to degrade gluten into non-toxic peptides.
- Other promising approaches include therapeutic vaccines and zonulin inhibitors.
Conclusions:
- There is a significant unmet need for coeliac disease treatments beyond a GFD.
- Oral glutenase supplements represent a likely breakthrough therapy.
- Therapeutic vaccines and zonulin inhibitors show promising results for coeliac disease management.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
739
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
739
01:17Drugs for Treatment of Diarrhea-Predominant IBS
993
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
993
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
683
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
683
01:21Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
694
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
694
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
863
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
863